Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$35.42 USD
-0.39 (-1.09%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $35.39 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 35.42 -0.39(-1.09%)
Will AGIO be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Here's Why Agios Stock Plummeted More Than 20% on Monday
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
4 Medical Product Stocks to Buy From a Prospective Industry
Other News for AGIO
TD Cowen Keeps Their Buy Rating on Agios Pharma (AGIO)
Agios Pharmaceuticals announces EC adopted positive decision for mitapivat
Agios Pharmaceuticals announces EC adopted positive decision for mitapivat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Agios Pharmaceuticals Shares Cross Below 200 DMA